(The following press release from Merck KGaA was received by e-mail. It was not confirmed by the sender.) News Release Your Contact Phyllis Carter +49 6151 72-7144 Merck Initiates TH-302 Phase III MAESTRO Study in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma • Pivotal Phase III study with investigational hypoxia-targeted drug aims to enroll 660 patients Darmstadt, Germany, January 25, 2013 – Merck today announced the initiation of the global Phase III MAESTRO study, assessing the efficacy and safety of investigational hypoxia-targeted drug TH-302 in combination with gemcitabine in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma. The study is being carried out pursuant to a global licensing and co-development agreement for TH-302 between Merck and Threshold Pharmaceuticals Inc., which includes an option for Threshold to co-commercialize in the U.S. MAESTRO stands for TH-302 in the treatment of MetastAtic or unrESectable pancreaTic adenocaRcinOma. The complete news release can be downloaded at the following link: http://news.merck.de/N/0/C129EE9000B3AE31C1257AFE002AF6CC/$File/MaestroEng.pdf Merck's news releases are available at this address: http://media.merck.de You may change your subscription at any time by following this link: http://subscribe.merck.de Unsubscribe this service with: http://news.merck.de/N/WEBOK?OpenForm&WA=2&FN=3&ID=2F7B430E0746A994C125782300588 64F ________________________________________________________________________________ ____________ Merck KGaA External Communications E-mail: Media.Relations@merck.de Hotline: +49 (0) 6151/72-5000 This message and any attachment are confidential and may be privileged or otherwise protected from disclosure. If you are not the intended recipient, you must not copy this message or attachment or disclose the contents to any other person. If you have received this transmission in error, please notify the sender immediately and delete the message and any attachment from your system. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not accept liability for any omissions or errors in this message which may arise as a result of E-Mail-transmission or for damages resulting from any unauthorized changes of the content of this message and any attachment thereto. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not guarantee that this message is free of viruses and does not accept liability for any damages caused by any virus transmitted therewith. Click http://disclaimer.merck.de to access the German, French, Spanish and Portuguese versions of this disclaimer.
MERCK KGAA STARTS TH-302 PHASE III STUDY ON PANCREAS CANCER(ENG)